Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy

Key Points

• This editorial examines the challenges faced in immune checkpoint inhibitor therapy for NSCLC.
• Discusses the efficacy of immune checkpoint inhibitors across different populations.
• Explores the resistance mechanisms that limit treatment effectiveness.
• Analyzes treatment-related toxicities associated with immune checkpoint inhibitors.
• Highlights inconsistent efficacy of immune checkpoint inhibitors in diverse patient groups.
• Identifies complex mechanisms of resistance to therapy.
• Notes the presence of treatment-related toxicities that affect patient outcomes.

Abstract